Shannon Youngblood has been elected as the new president of the SNMMI Technologist Section. She will focus on amplifying visibility through advocacy, building a more inclusive workforce through educational opportunities, and streamlining professional development to stay current with advancements in theranostics and cardiac PET-CT.
A new type of peptide receptor radionuclide therapy (PRRT) shows promise in treating metastatic neuroendocrine tumors. The novel approach resulted in partial remission in the majority of patients with advanced cases, with manageable safety and encouraging antitumor activity.
Researchers developed a novel PET imaging approach to detect immune-related adverse events in patients receiving immunotherapy. The approach uses CCR2-targeted radiotracer to visualize both tumor progression and cardiac inflammatory responses. Co-treatment with itacitinib improved tumor response while reducing cardiac inflammation.
Dr. Richard E. Carson has made significant contributions to the understanding and application of nuclear medicine, particularly in neuroscience and neuropsychiatric disorders. His work led to the development of diverse tracer kinetic modeling techniques and innovative imaging systems like NeuroEXPLORER.
A study found that a specific pattern of brain metabolism visualized with PET imaging can predict which patients are most likely to benefit from Alzheimer's disease therapy. Patients with this pattern experienced stabilized cognitive performance, while those with other patterns had significant cognitive decline.
A new SPECT/CT imaging approach can accurately differentiate between inflammation and fibrosis in interstitial lung disease (ILD) patients. Researchers used the molecular imaging agent ⁹⁹ᵐTc-maraciclatide to visualize inflammation, which is crucial for determining treatment decisions.
Vasken Dilsizian, MD, has received the Minoshima-Pappas Transformational Leadership Award for his vision and leadership in advancing nuclear medicine and molecular imaging. He has made significant contributions to the field of cardiovascular diseases through his innovative scientific work.
A new machine-learning model uses pre-therapy PET/CT scans to estimate radiation dose to tumors and healthy organs, improving patient selection and reducing toxicity risk. The study's findings suggest a promising ability to predict post-therapy dosimetry, which may optimize treatment plans for individual patients.
The Society of Nuclear Medicine and Molecular Imaging recognized six new Fellows for their exceptional contributions to the field. The SNMMI Fellowship honors members who have demonstrated excellence in scientific discovery, educational efforts, or clinical practice.
Researchers have made significant breakthroughs in nuclear medicine, with studies revealing uneven radiation doses in tiny kidney structures, improving survival rates for prostate cancer patients through targeted radiation therapy, and developing a new PET imaging approach to detect abdominal cancer spread. These advancements aim to im...
Recent studies published in The Journal of Nuclear Medicine investigate the safety of kidney treatments, effectiveness of radioactive iodine for dialysis patients, and the use of new PET imaging agents to detect breast cancer spread. Researchers also explored emerging techniques like FAPI PET scans for improved detection and treatment ...
Recent research published in The Journal of Nuclear Medicine has made significant advancements in brain imaging and cancer treatment. A new wearable brain imaging system, SmartBrain, enables real-time imaging beyond the lab, capturing high-resolution images of brain activity without requiring patients to remain still.
A new pretargeted radioimmunotherapy technique has been shown to be effective and safe in eradicating tumors from a preclinical colorectal cancer model. The multi-step theranostic approach delivers alpha-emitting radiation directly to tumors while limiting exposure to healthy tissues.
Scientists successfully built the smallest X-ray interferometer to measure how X-rays interact with atomic nuclei. This breakthrough technology enables precise measurement of X-ray refraction and provides new avenues for research.
Researchers have made significant breakthroughs in prostate cancer treatment with new imaging techniques and targeted therapies, including a PSMA-targeting antibody and a CD44v6-targeting radiotherapy. These advancements aim to improve patient outcomes by tailoring diagnosis and treatment to individual needs.
Salk scientists and collaborators advance visualization technology using visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs), reducing background fluorescence by up to a hundredfold. The new probe enables high spatial and temporal precision, allowing for real-time tracking of dynamic changes in living models.
The SNMMI 2026 Annual Meeting will showcase the latest scientific developments driving advances in nuclear medicine, including earlier diagnosis, personalized treatment, and improved disease management for various conditions. The meeting will feature over 150 scientific sessions, satellite symposia, and a cutting-edge exhibit hall.
A new PET biomarker outperforms established risk scores in predicting survival for large B-cell lymphoma patients. Metabolic tumor volume, derived from PET imaging, was found to be an important predictor of progression-free survival.
Researchers developed a new chelator to improve cancer imaging and therapy. Additionally, analyzing brain glucose uptake in patients with non–small cell lung cancer may help predict prognosis. A targeted PET imaging agent is also being developed to detect liver cancer more effectively.
A new optical-coupled scanning probe microscope uses a remote liquefaction cryogen-free system to visualize individual atoms and probe electronic and chemical properties without freezing budget. The system achieves stable base temperature and low noise levels, making it ideal for continuous experiments and studies of slow processes.
Researchers have developed new PET tracers that can track synaptic density in epilepsy and monitor tau buildup in Alzheimer's disease. A novel PET tracer also maps cellular energy use across the body, enabling faster imaging approaches for studying mitochondrial function.
Recent studies published in The Journal of Nuclear Medicine have made significant advancements in the field. Researchers have developed a new tracer to detect active collagen turnover following myocardial infarction and evaluated folate-based radioconjugates for ovarian cancer imaging. Additionally, targeted radiotherapy shows promise ...
Kiran Solingapuram Sai's research aims to detect microtubule dysfunction early in Alzheimer's disease using a first-in-class PET radiotracer. The study will establish a reproducible imaging framework for this target.
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Researchers Ansel Hillmer and Eric Webb have received the $100,000 Drs. Jane & Abass Alavi Mars Shot Research Award to advance imaging research in infection and inflammation for Alzheimer's disease. They aim to develop a PET radiotracer targeting CSF1R to diagnose and monitor brain inflammation.
Dr. Carolyn J. Anderson has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop a PET radiotracer for imaging vaso-occlusive crisis in sickle cell disease. The award will support the production and validation of an easy-to-produce and high-yielding PET radiotracer, 18F-LLP2A, for rapid translation to patients.
The study investigated the link between heart attack-induced inflammation and cognitive decline, as well as the potential of PET-based metabolic tumor volume to predict CAR T-cell therapy outcomes. Additionally, researchers combined advanced imaging with genetic profiling to explore hidden metabolic patterns in recurrent brain cancer.
Researchers Haj-Mirzaian and Heidari aim to develop non-invasive imaging biomarker <sup> 18 </sup> F-NaF PET/CT for early calciphylaxis diagnosis in dialysis-dependent patients. This could lead to timely interventions, reduced mortality, and improved patient outcomes.
Dr. Chun Li has been awarded the SNMMI Mars Shot Research Fund Award to investigate the PET radiotracer 64Cu-DbCD11b for detecting vulnerable atherosclerotic plaques. The study aims to assess the non-invasive assessment of vulnerable plaques and aid in patient risk identification and treatment.
Dr. David H. Ballard, MD, has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop novel PET/MR imaging techniques for metabolic activity and inflammation in Crohn's disease. The study aims to improve biologically informed decision-making and guide treatment decisions.
Researchers have developed new imaging techniques to detect hidden infections, inflammatory diseases, and cancers, while also evaluating the effectiveness of AI-powered tumor measurement and targeted radiotherapy for advanced solid tumors.
A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients as little as four weeks after treatment initiation. The imaging technique uses macrophages, a type of white blood cell, as a biomarker for disease activity, potentially allowing non-responders to pursue more effective therapies.
Researchers have developed a new PSMA-targeted PET tracer that shows promise in early human studies, providing strong tumor uptake and favorable radiation dosimetry. Additionally, advanced dynamic PET imaging has been used to track heart amyloid buildup more precisely, detecting significant reductions after six months of tafamidis ther...
A novel quantitative imaging approach using PET and MRI can identify limbic-predominant age-related TDP-43 encephalopathy (LATE), a distinct neurodegenerative disorder resembling Alzheimer's disease. This framework may guide targeted diagnostic work-up and personalized care for dementia patients.
Researchers have made significant advancements in nuclear medicine by developing a new reporting framework for PET/CT scans, using targeted radiation therapy to treat sarcoma, and investigating how genetic mutations affect prostate cancer treatment outcomes. These studies aim to improve diagnosis and treatment for various cancers.
Scientists have created a way to hear a single molecule 'sing' using infrared-integrated STM. This technique combines infrared excitation with scanning tunneling microscopy, allowing for the detection of individual molecular vibrations.
Researchers are testing new targeted radiation approaches for early colorectal cancer, HER2-positive breast cancer, and advanced prostate cancer. Imaging tools track treatment movement and help evaluate dosing and safety.
Ken Herrmann will lead the journal for five years, focusing on global engagement and impact. He succeeds Johannes Czernin, who guided JNM through significant growth and expansion.
The University of Missouri has launched its first human clinical trial using Eye90 microspheres, a radiopharmaceutical breakthrough device manufactured on campus. The study aims to assess the safety and effectiveness of Eye90 in treating unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer.
Researchers used advanced PET imaging techniques to study the effects of traumatic spinal cord injuries on nerve cells. Additionally, whole-body PET scans were used to map brain-body immune cross-talk during immune responses.
Researchers have developed new CXCR4-targeting radiolabeled peptides for cancer imaging and therapy, producing clear tumor images and extending survival in preclinical testing studies. Additionally, PET scans are being used to predict prostate cancer outcomes, identify primary aldosteronism, and guide treatment decisions.
Researchers developed a novel combined PET imaging approach to personalize radiotherapy for head and neck cancers, creating biologic maps that show tumor characteristics. This strategy led to greater than 90% predicted tumor control probability, outperforming previous literature.
This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.
Scientists have developed a new technique that combines rotational ultrasound tomography (RUST) with photoacoustic tomography (PAT) to create 3D color images of soft tissues and blood vessel function. This method has the potential to enhance breast tumor imaging, monitor nerve damage caused by diabetes, and brain imaging.
Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...
Researchers at IIT develop optical microscopy technique that combines polarization and dark-field microscopy to observe cells with high contrast, preserving their natural conditions. The next step involves using AI to enrich images with molecular information related to diseases.
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.
Researchers developed new imaging approaches using specialized amino acid PET tracers to visualize aggressive breast, lung, and glioma cancers. The studies showed promising results, highlighting the potential of these tools for future cancer imaging and guiding targeted therapies.
Researchers have developed new PET imaging tracers to detect and treat colorectal, thyroid, and lymphoma cancers. The tracers enable targeted radiation delivery, personalized dosing, and improved detection of inflammation in large blood vessels and liver lesions.
A team of MIT engineers developed a deep-learning model that predicts how individual cells will fold, divide, and rearrange during a fruit fly's earliest stage of growth. The model achieved 90% accuracy in predicting the movement of 5,000 cells over the first hour of development.
Recent studies explored novel biomarkers for kidney cancer spread detection, heart scans for ATTR amyloidosis diagnosis, and radiation therapy delivery for neuroendocrine tumors. Additionally, researchers developed a new PET tracer to track heart-healing cells after a heart attack.
Researchers developed multimodal models integrating imaging, clinical, and molecular data from TAILORx tissue biorepository for early-stage breast cancer. The models demonstrated enhanced prognostic performance compared to existing methods, highlighting their potential for personalized treatment decision-making.
This supplement highlights key areas of focus for theranostics, including clinical lessons, education, science, multidisciplinary collaboration, and equity. It also explores new frontiers beyond oncology and examines finance, sustainability, policy, strategy, and future directions.
Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...
Several studies examine imaging tools for detecting prostate cancer, testing new PET tracers for spotting aggressive tumors. Researchers also explored a new scan to detect gastrointestinal stromal tumors and improved imaging agents for pancreatic cancer diagnosis.
Researchers have made significant advancements in detecting and treating prostate cancer and ALS using innovative imaging techniques. A new PET tracer has been developed to track Huntington disease protein aggregates, offering a potential noninvasive monitoring tool. Additionally, studies have compared two types of PET scans for spotti...
The Society of Nuclear Medicine and Molecular Imaging emphasizes the importance of education, training, and experience for safe and effective delivery of radiopharmaceutical therapy. Specialized expertise is needed to handle radioactive compounds and ensure patient safety.
A new radioimmunotherapy approach has been developed to treat HER2-positive breast cancer, resulting in complete and histologic cures with minimal toxicities. The treatment uses a pretargeted approach to directly target tumors, reducing the risk of radiation toxicity to healthy tissues.
Researchers developed a detailed kidney model to study radiation distribution, highlighting uneven exposure across different nephron types. Tumor volume changes and PSMA PET imaging also showed promise for predicting outcomes in prostate cancer patients. New targeted therapies and imaging strategies aim to improve diagnosis and treatment.
Researchers at the University of Queensland have captured high-resolution images of the yellow fever virus, shedding light on its structural differences between the vaccine strain and disease-causing variants. The study reveals that these differences impact how the immune system recognizes the virus.